1335 related articles for article (PubMed ID: 17173260)
1. Membranoproliferative glomerulonephritis in a patient with Wilson's disease.
Ozçakar ZB; Ekim M; Ensari A; Kuloglu Z; Yüksel S; Acar B; Kirsaçlioglu C; Kansu A; Yalçinkaya F; Girgin N
J Nephrol; 2006; 19(6):831-3. PubMed ID: 17173260
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease.
Ping CC; Hassan Y; Aziz NA; Ghazali R; Awaisu A
J Clin Pharm Ther; 2007 Feb; 32(1):101-7. PubMed ID: 17286794
[TBL] [Abstract][Full Text] [Related]
3. Hypothyroidism and dyshormonogenesis induced by D-penicillamine in children with Wilson's disease and healthy infants born to a mother with Wilson's disease.
Hanukoglu A; Curiel B; Berkowitz D; Levine A; Sack J; Lorberboym M
J Pediatr; 2008 Dec; 153(6):864-6. PubMed ID: 19014823
[TBL] [Abstract][Full Text] [Related]
4. Wilson's disease: long-term follow-up of a cohort of 24 patients treated with D-penicillamine.
Lowette KF; Desmet K; Witters P; Laleman W; Verslype C; Nevens F; Fevery J; Cassiman DM
Eur J Gastroenterol Hepatol; 2010 May; 22(5):564-71. PubMed ID: 20042865
[TBL] [Abstract][Full Text] [Related]
5. [Nephrotic syndrome after treatment with d-penicillamine in a pediatric patient with Wilson's disease].
Farallo M; Amoruso C; Frattini C; Ardissino G; Nebbia G
Pediatr Med Chir; 2012; 34(5):234-6. PubMed ID: 23342748
[TBL] [Abstract][Full Text] [Related]
6. Early onset of nephrotic syndrome after treatment with D-penicillamine in a patient with Wilson's disease.
Siafakas CG; Jonas MM; Alexander S; Herrin J; Furuta GT
Am J Gastroenterol; 1998 Dec; 93(12):2544-6. PubMed ID: 9860423
[TBL] [Abstract][Full Text] [Related]
7. Withdrawal of penicillamine from zinc sulphate-penicillamine maintenance therapy in Wilson's disease: promising, safe and cheap.
Sinha S; Taly AB
J Neurol Sci; 2008 Jan; 264(1-2):129-32. PubMed ID: 17765927
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and management of Wilson's disease: results of a single center experience.
Medici V; Trevisan CP; D'Incà R; Barollo M; Zancan L; Fagiuoli S; Martines D; Irato P; Sturniolo GC
J Clin Gastroenterol; 2006; 40(10):936-41. PubMed ID: 17063115
[TBL] [Abstract][Full Text] [Related]
9. Epileptic status immediately after initiation of D-penicillamine therapy in a patient with Wilson's disease.
Berger B; Mader I; Damjanovic K; Niesen WD; Stich O
Clin Neurol Neurosurg; 2014 Dec; 127():122-4. PubMed ID: 25459257
[No Abstract] [Full Text] [Related]
10. Treatment of Wilson's disease with triethylene tetramine dihydrochloride. A case report.
Haslam RH; Sass-Kortsak A; Stout W; Berg M
Dev Pharmacol Ther; 1980; 1(5):318-24. PubMed ID: 7438976
[TBL] [Abstract][Full Text] [Related]
11. [Pathogenesis and treatment of Wilson's disease].
Nagy J; Vincze Z; Folhoffer A; Horváth A; Csák T; Zelkó R
Acta Pharm Hung; 2003; 73(4):237-41. PubMed ID: 15279036
[TBL] [Abstract][Full Text] [Related]
12. Myelopathy secondary to copper deficiency as a complication of treatment of Wilson's disease.
Lozano Herrero J; Muñoz Bertrán E; Ortega González I; Gómez Espín R; López Espín MI
Gastroenterol Hepatol; 2012 Dec; 35(10):704-7. PubMed ID: 22609346
[TBL] [Abstract][Full Text] [Related]
13. Wilson's disease.
Walshe JM
Lancet; 2007 Mar; 369(9565):902. PubMed ID: 17368141
[No Abstract] [Full Text] [Related]
14. Concurrent massive breast enlargement, myasthenia gravis and dermopathy as manifestations of penicillamine toxicity in a Wilson's disease patient.
Tan SS; Latif SA; Poh WY
Med J Malaysia; 2012 Jun; 67(3):323-5. PubMed ID: 23082426
[TBL] [Abstract][Full Text] [Related]
15. [The onset of psychiatric disorders and Wilson's disease].
Benhamla T; Tirouche YD; Abaoub-Germain A; Theodore F
Encephale; 2007 Dec; 33(6):924-32. PubMed ID: 18789784
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of oral chelators in treatment of patients with Wilson disease.
Weiss KH; Thurik F; Gotthardt DN; Schäfer M; Teufel U; Wiegand F; Merle U; Ferenci-Foerster D; Maieron A; Stauber R; Zoller H; Schmidt HH; Reuner U; Hefter H; Trocello JM; Houwen RH; Ferenci P; Stremmel W;
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1028-35.e1-2. PubMed ID: 23542331
[TBL] [Abstract][Full Text] [Related]
17. Zinc therapy increases duodenal concentrations of metallothionein and iron in Wilson's disease patients.
Sturniolo GC; Mestriner C; Irato P; Albergoni V; Longo G; D'Incà R
Am J Gastroenterol; 1999 Feb; 94(2):334-8. PubMed ID: 10022625
[TBL] [Abstract][Full Text] [Related]
18. Effect of penicillamine and zinc on iron metabolism in Wilson's disease.
Medici V; Di Leo V; Lamboglia F; Bowlus CL; Tseng SC; D'Incà R; Irato P; Burra P; Martines D; Sturniolo GC
Scand J Gastroenterol; 2007 Dec; 42(12):1495-500. PubMed ID: 17994470
[TBL] [Abstract][Full Text] [Related]
19. D-penicillamine-induced ANA (+) ANCA (+) vasculitis in pediatric patients with Wilson's disease.
Lee Y; Lee ST; Cho H
Clin Nephrol; 2016 May; 85(5):296-300. PubMed ID: 26784915
[TBL] [Abstract][Full Text] [Related]
20. [Late presentation of Wilson's disease].
Santander Vaquero C
Rev Esp Enferm Dig; 2002 Aug; 94(8):502-3. PubMed ID: 12486857
[No Abstract] [Full Text] [Related]
[Next] [New Search]